A new class of antiemetics: The NK-1 receptor antagonists

Current Opinion in Oncology

Volumn 12, Issue 4, 2000, Pages 284-288

  Bleiberg, Harry ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CORTICOSTEROID; EZLOPITANT; L 750030; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 AGONIST; UNCLASSIFIED DRUG;

CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; VOMITING;

EID: 0034516926     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200007000-00002     Document Type: Review

References (21)

1. Tachykinin receptors in gastrointestinal motility
2. Neurotransmitter functions of mammalian tachykinin
3. Substance P
4. Neuropeptides and inflammation: The role of substance P
5. Substance P and the neurokinins: Novel peptide nerotransmitters in psychopharmacology
6. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain
7. The anti-emetic effects of CP99,994 in the ferret and the dog: Role of the NK receptor
8. The site of the anti-emetic action of tachykinin NK, receptor antagonists may exist in the medullary area adjacent to the semicompact part of the nucleus ambiguous
9. Immunohistochemical study of neuropeplides in vagal glossopharyngeal afferent neurons in the rat
10. Neurons in the nucleus of the solitary tract mediating inpts from emetic vagal afferent and the area postrema to the pattern generator for the emetic act in dogs
11. Recommendations for the use of antiemetics: Evidence-based clinical practice guidelines
12. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
13. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotheerapy- naive patients and patients pretreated with fluorouracil-based chemotherapy
14. Randomized phase II study of the neurokinin 1 receptor anagonists CJ11,974 in the control of cisplatin-induced emesis
15. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
16. Anti-emetic profile of a non-peptide neurokinin NK, receptor antagonist CP-99,994 in ferrets
17. The tachykinins and emesis: Towards complete control
18. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin receptor antagonist CP99,994
19. Control of emesis following cisplatin by CP122,721, a selective NK, receptor antagonist
20. Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antogonist
21. Comparison of neurokinin-1 antagonist L-758,298 to ondansetron in the prevention of cisplatin induced emesis